AngioDynamics’ pivot toward faster-growing, higher-margin Med Tech platforms could unlock a valuation re-rating, but cash use, manufacturing execution and clinical adoption make the transformation a high-variance investment.
AngioDynamics, Inc. (NASDAQ: ANGO) is a medical technology company engaged in the design, manufacture, and commercialization of minimally invasive medical devices and technological platforms [cite: 1, 2]. The company’s product portfolio serves interventional radiologists, vascular surgeons, interventional cardiologists, and surgical oncologists worldwide [cite: 1, 2]. Over recent fiscal periods, AngioDynamics has undertaken a multi-year strategic transformation, reallocating capital away from mature, lower-margin vascular access and general surgical devices toward proprietary, high-growth medical technology platforms [cite: 2, 3].
The enterprise operates through two principal reporting segments: Med Tech and Med Device [cite: 1, 4]. Revenue is generated predominantly through the sale of single-use disposable catheter kits, procedural packs, and associated capital equipment consoles [cite: 1, 5]. In fiscal year 2026, the company generated $320.2 million in total net sales, representing a 9.5% year-over-year expansion [cite: 2, 6]. The Med Tech segment contributed $150.0 million (up 18.4% year-over-year), while the Med Device segment recorded $170.2 million (up 2.5% year-over-year) [cite: 4]. The United States represents the dominant geographic revenue base, generating approximately 88% to 90% of total sales, with international distribution channels accounting for the remainder [cite: 1, 7].
| Business Segment | FY2026 Net Sales | YoY Organic Growth | Segment Gross Margin | Core Product Lines | Primary Clinical Target |
|---|---|---|---|---|---|
| Med Tech | $150.0M (46.8%) [cite: 4] | +18.4% [cite: 4] | ~64.3% [cite: 4] | Auryon, AlphaVac, AngioVac, NanoKnife [cite: 1, 4, 8] | Vascular disease, PE/DVT, localized oncology [cite: 4, 8] |
| Med Device | $170.2M (53.2%) [cite: 4] | +2.5% [cite: 4] | ~44.4% [cite: 4] | Dialysis catheters, Vascular ports, Microwave ablation [cite: 1] | Dialysis access, systemic drug delivery, general care [cite: 1] |
| Total Enterprise | $320.2M (100.0%) [cite: 2, 6] | +9.5% [cite: 2, 6] | ~54.6% [cite: 9] | Consolidated Portfolio [cite: 1] | Global Healthcare Institutions [cite: 1] |
The Med Tech portfolio is built upon three flagship proprietary technology platforms [cite: 1, 4, 8]:
* Auryon Atherectomy System: A solid-state laser catheter system operating at a 355nm wavelength designed to treat peripheral artery disease (PAD) [cite: 4, 8, 10]. Auryon vaporizes calcified and lesions across above-the-knee (ATK), below-the-knee (BTK), and in-stent restenosis (ISR) presentations while preserving vessel wall structural integrity [cite: 4, 8, 10].
* Thrombus Management Systems (AlphaVac & AngioVac): Non-surgical mechanical thrombectomy devices engineered to aspirate thrombi and emboli from the peripheral vasculature [cite: 4, 8, 11]. AlphaVac features an off-circuit suction design and ergonomic manual handle for precise control in deep vein thrombosis (DVT) and pulmonary embolism (PE) procedures [cite: 4, 8, 11].
* NanoKnife System: An Irreversible Electroporation (IRE) platform that delivers controlled, non-thermal electrical pulses to induce unrecoverable cell membrane disruption [cite: 2, 8, 11]. NanoKnife ablates focal targeted soft tissue in delicate anatomical regions—such as localized prostate and pancreatic lesions—without compromising adjacent collagenous structures, nerve bundles, or critical blood vessels [cite: 2, 4, 8, 11].
The Med Device portfolio comprises legacy products, including angiographic catheters, peritoneal dialysis catheters, vascular access ports, and radiofrequency/microwave ablation consoles [cite: 1]. While mature, this segment generates baseline operating cash flow that supports research and development in Med Tech [cite: 5].
AngioDynamics serves acute-care hospital systems, outpatient surgical centers (ASCs), and physician-owned office-based labs (OBLs) [cite: 4]. End markets encompass interventional oncology, vascular care, interventional cardiology, and general vascular health [cite: 1, 4].
Clinicians select AngioDynamics products due to their therapeutic precision and safety profiles [cite: 2, 4, 8]. Auryon addresses complex calcified lesions without the thermal tissue degradation or perforation risks associated with alternative mechanical atherectomy tools [cite: 4, 8, 10]. NanoKnife offers a non-thermal ablation modality in anatomical zones where thermal techniques (radiofrequency or cryoablation) risk causing severe structural damage or organ dysfunction [cite: 2, 4, 8].
AngioDynamics' overarching strategy focuses on converting its operating profile from a low-margin, mature medical supplier into a pure-play, high-margin medical technology enterprise [cite: 2, 3]. Management has pursued portfolio pruning by divesting legacy product lines and executing a comprehensive manufacturing restructuring program [cite: 2, 3, 12]. By outsourcing the majority of physical assembly while retaining core sub-assembly operations in Queensbury, New York, the company aims to eliminate fixed facility overhead and capture approximately $15 million in annual structural cost savings upon completion in fiscal 2027 [cite: 2, 12].
Revenue growth is anchored by expanding utilization of Med Tech disposables [cite: 5]. Because disposable catheters represent high-margin recurring purchases, clinical adoption directly expands corporate gross margins [cite: 4, 5, 7].
* Auryon Expansion: Auryon represents the primary top-line engine, registering continuous double-digit quarterly revenue gains [cite: 4, 13]. Growth is driven by expanding clinical trial validation, such as the AMBITION trial for below-the-knee (BTK) peripheral artery disease, and transitioning catheter volume into high-density hospital networks and OBL settings [cite: 4, 10].
* AlphaVac and VTE Indications: Mechanical thrombectomy growth stems from market adoption of AlphaVac in venous thromboembolism (VTE) [cite: 4, 8, 11]. The initiation of key clinical studies, including the APEX-Return study for pulmonary embolism, provides clinical evidence to capture market share from traditional chemical thrombolytics and rival mechanical systems [cite: 4, 10, 11].
* NanoKnife Focal Ablation Expansion: NanoKnife’s expansion is supported by clinical data from the DIRECT registry for stage III pancreatic cancer and expanding Medicare coverage for focal prostate ablation [cite: 2, 8, 11]. The transition toward office-based urological procedures provides a recurring, high-margin single-use probe consumption stream [cite: 4, 5].
According to corporate disclosures, AngioDynamics is executing against a total addressable market in the United States projected to expand from $7.2 billion in fiscal 2026 to $10.9 billion across the fiscal 2027–2031 planning horizon [cite: 4].
| Market Category / Clinical Indication | Estimated Target US TAM | Core Platform Solution | Primary Growth Catalysts |
|---|---|---|---|
| Deep Vein Thrombosis (DVT) | $2.80 Billion [cite: 4] | AlphaVac / AngioVac [cite: 4, 8] | Shift from thrombolytic drugs to mechanical thrombectomy [cite: 4, 8] |
| Prostate Diseases (Prostate Cancer & BPH) | $2.83 Billion [cite: 4] | NanoKnife System [cite: 2, 4, 8] | Focal tissue-sparing therapy adoption; expanded Medicare coverage [cite: 2, 8, 11] |
| Pulmonary Embolism (PE) | $2.40 Billion [cite: 4] | AlphaVac Multipurpose [cite: 4, 8] | APEX-PE trial data; PERT hospital protocol integrations [cite: 4, 11] |
| Peripheral Artery Disease (PAD) | $800 Million [cite: 4] | Auryon System [cite: 4, 8] | AMBITION trial readouts; BTK and ISR indication expansion [cite: 4, 10] |
| Coronary & Cardiac Indications | $1.94 Billion [cite: 4] | Auryon / AlphaVac [cite: 4, 8] | Coronary atherectomy clearance; infective endocarditis IDEs [cite: 4] |
AngioDynamics possesses a narrow economic moat defined by proprietary intellectual property, clinical data integration, and hospital switching costs [cite: 2, 4, 8].
* Proprietary Intellectual Property: The 355nm solid-state laser technology used in Auryon and the controlled electrical field delivery algorithms in NanoKnife are protected by extensive patent families [cite: 2, 8]. This prevents direct generic engineering by competitors [cite: 2, 8].
* Switching Costs and Technical Integration: Operating the NanoKnife ablation console or the Auryon laser system requires specialized training for surgical oncologists and interventionalists [cite: 2, 8]. Once an institution commits capital budget dollars to install a capital console, clinical workflows adapt around the system, generating long-term single-use disposable catheter and probe utilization [cite: 5].
* Regulatory Barriers and Clinical Evidence: Obtaining FDA Investigational Device Exemptions (IDEs) and completing randomized clinical trials (such as DIRECT and APEX) require significant capital and multi-year execution timelines [cite: 2, 4, 11]. Competitors face long lead times to replicate these clinical data sets and secure reimbursed indication approvals [cite: 2, 4].
The company operates alongside both consolidated multi-national device conglomerates and focused medical technology firms [cite: 14].
| Product Segment | Key Competitors | AngioDynamics Strategic Position | Market Share Momentum |
|---|---|---|---|
| Laser Atherectomy | Boston Scientific, Philips (Spectranetics), Cardiovascular Systems (Abbott) | Solid-state laser technology capable of treating all plaque morpholoiges without vessel wall injury [cite: 4, 8, 10] | Gaining market share in complex BTK and ISR cases [cite: 4, 10] |
| Mechanical Thrombectomy | Inari Medical, Penumbra, Boston Scientific | Dual portfolio offering manual precision (AlphaVac) and high-volume venous circuit aspiration (AngioVac) [cite: 4, 8, 11] | Holding share in core DVT; actively building PE presence [cite: 4, 11] |
| Non-Thermal Soft Tissue Ablation | Johnson & Johnson, Medtronic, EDAP TMS | Monopolistic positioning in non-thermal Irreversible Electroporation (IRE) [cite: 2, 8] | Gaining market share in focal prostate soft tissue ablation [cite: 2, 4] |
| Vascular Access & Ports | Becton Dickinson (BD), Teleflex, Merit Medical | Established cash-generative supplier of standard vascular access equipment [cite: 1, 5, 14] | Baseline share in mature product categories [cite: 4, 5] |
AngioDynamics announced its first quarter fiscal year 2027 financial results on October 8, 2026, covering the three-month operational period ended August 31, 2026 [cite: 12, 15].
| Q1 FY2027 Financial Snapshot | Reported Q1 FY27 | Reported Q1 FY26 | YoY Change | Consensus Estimate | Surprise / Performance vs Expectation |
|---|---|---|---|---|---|
| Total Net Sales | $80.92M [cite: 7] | $75.71M [cite: 7] | +6.9% [cite: 12] | $80.50M [cite: 5] | Beat (+$0.42M) [cite: 5] |
| Med Tech Sales | $39.90M [cite: 5] | $35.24M [cite: 5] | +13.2% [cite: 5, 7] | N/A | Exceeded internal tracking [cite: 5] |
| Med Device Sales | $41.02M [cite: 5] | $40.47M [cite: 5] | +1.4% [cite: 5, 13] | N/A | Aligned with flat guidance [cite: 5, 13] |
| GAAP Gross Margin | 59.4% [cite: 5, 12] | 55.3% [cite: 5, 12] | +410 bps [cite: 12] | 55.0% [cite: 5] | Beat (+440 bps) [cite: 5, 12] |
| Adjusted Gross Margin | 57.8% [cite: 5] | 55.3% [cite: 5] | +250 bps [cite: 5] | N/A | Strong operational expansion [cite: 5, 7] |
| GAAP Net Loss | $(7.10)M [cite: 12] | $(10.90)M [cite: 12] | +34.9% [cite: 7] | N/A | Loss narrowed by $3.8M [cite: 7, 12] |
| Adjusted EPS | $(0.04) [cite: 5, 15] | $(0.10) [cite: 5] | +60.0% [cite: 5] | $(0.11) [cite: 5, 15] | Beat (+$0.07 beat) [cite: 5, 15] |
| Adjusted EBITDA | $5.00M [cite: 5, 13] | $2.20M [cite: 5] | +127.3% [cite: 5, 13] | $3.10M [cite: 4] | Beat (+$1.90M) [cite: 4, 5] |
| Cash & Equivalents | $34.00M [cite: 12] | $53.90M (FY26 End) [cite: 12] | -$19.9M [cite: 12] | N/A | Cash burn focused in working capital [cite: 12] |
During the Q1 FY2027 earnings presentation, management reaffirmed its full-year fiscal 2027 guidance targets [cite: 5, 13]:
* Net Sales Guidance: $336.0 million to $341.0 million (5.0% to 6.5% total growth) [cite: 4, 5].
* Med Tech Growth Target: 12.0% to 15.0% organic expansion [cite: 4, 5].
* Med Device Target: Roughly flat year-over-year revenue [cite: 4, 5].
* Gross Margin: 54.0% to 55.0% [cite: 4, 5].
* Adjusted EBITDA: $13.0 million to $16.0 million [cite: 4, 5].
* Adjusted EPS: $(0.29) to $(0.24) [cite: 4, 5].
* Operating Cash Flow: Projected to be positive for the full fiscal year [cite: 4, 5].
Key management commentary centered on two primary themes: the ongoing business mix shift and executive succession [cite: 3, 5, 12]. Management reiterated that Med Tech is on track to represent over 50% of total revenue during fiscal 2027 [cite: 3, 5]. Additionally, the Board announced the appointment of Eric Honroth as President, Chief Executive Officer, and Board member effective November 2, 2026, following the planned retirement of James Clemmer [cite: 12, 16].
Following the Q1 FY27 earnings release, ANGO stock experienced moderate short-term selling pressure, dropping between 3% and 7% in pre-market and early trading sessions [cite: 5, 17]. Although top-line and bottom-line figures beat Wall Street expectations, market participants reacted to the sequential drawdown in cash balances ($34.0 million versus $53.9 million at the close of FY26) driven by seasonal working capital cash use and ongoing restructuring expenses [cite: 5, 12]. Analyst price targets post-earnings remained steady, with the target range centered between $19.00 and $20.00 per share [cite: 11, 14, 17, 18].
The primary financial driver for AngioDynamics' valuation is the structural shift in product mix [cite: 3, 5]. Pure-play medical technology businesses characterized by gross margins above 65% trade at typical sales multiples ranging between 4.0x and 7.0x. Conversely, commodity medical device suppliers trade at lower multiples (1.0x to 2.0x sales). AngioDynamics' current valuation (1.84x sales) reflects its legacy med-device drag and GAAP net losses [cite: 1, 2, 6]. As Med Tech revenues expand to comprise over 60% of total sales and manufacturing outsourcing expands gross margins toward 58–60%, valuation multiples are likely to re-rate toward med-tech industry peer averages [cite: 2, 3, 5, 12].
The transition to Chief Executive Officer Eric Honroth on November 2, 2026, introduces operational continuity risk [cite: 12, 16]. Leadership changes can lead to modifications in commercial execution or shifts in capital allocation across R&D pipelines [cite: 7, 12, 16]. Simultaneously, the company is executing its manufacturing restructuring program, which carries estimated cash costs between $33.4 million and $38.4 million through Q2 FY27 [cite: 2, 12]. Disruptions in supply handoffs to third-party manufacturers could cause temporary supply chain delays or backlog accumulation [cite: 2, 12].
AngioDynamics competes against larger medical technology companies, including Inari Medical, Penumbra, Boston Scientific, and Abbott [cite: 14]. Competitors possess greater financial capacity to expand sales forces, fund clinical trials, and offer bundled purchasing discounts to hospital networks [cite: 14]. Price competition or aggressive product launches in the mechanical thrombectomy segment could slow AlphaVac adoption rates [cite: 4, 8, 14].
As of August 31, 2026, cash and cash equivalents totaled $34.0 million, representing a sequential drawdown from $53.9 million as of May 31, 2026 [cite: 12]. The company maintains an unencumbered $25.0 million revolving credit facility [cite: 4, 12]. However, borrowing capacity under this facility is subject to a $5.0 million liquidity reduction (limiting net availability to $20.0 million) until AngioDynamics achieves a Fixed Charge Coverage Ratio exceeding 1.10 to 1.00 [cite: 12]. Continued operational cash burn prior to achieving sustained positive free cash flow could constrain strategic growth investments [cite: 5, 12].
AngioDynamics remains exposed to hospital purchasing budget cycles, healthcare labor shortages, and international supply chain costs [cite: 1, 3]. Although gross margins benefited from $1.3 million in duty tariff refunds during Q1 FY27, changes in foreign trade policy or component supply tariffs could increase raw material costs and exert downward pressure on gross margins [cite: 3, 5, 7].
| Risk Category | Key Vulnerability Event | Early Warning Indicator | Thesis Impact Level |
|---|---|---|---|
| Execution Risk | Manufacturing outsourcing delays cause component supply shortfalls [cite: 2, 12] | Order backlog growth above $5.0M; gross margin drop below 52% [cite: 4, 5, 12] | Moderate: Transitory margin compression [cite: 2, 12] |
| Competitive Risk | Competitors launch next-generation mechanical thrombectomy tools [cite: 4, 8, 14] | AlphaVac quarterly sales growth decelerating below 10% [cite: 5, 7] | High: Dampens top-line growth acceleration [cite: 3, 4] |
| Capital Allocation Risk | Operational cash use exceeds seasonal forecasts, draining reserves [cite: 12] | Total cash and facility availability falling below $25.0M [cite: 12] | Critical: Requires dilutive equity capital raise [cite: 12] |
| Regulatory Risk | FDA requests additional clinical trials for NanoKnife prostate indication [cite: 2, 4, 11] | Delay in Medicare coverage determination timelines [cite: 11] | Thesis Killer: Impairs expansion into $2.8B prostate TAM [cite: 2, 4] |
The 5-year financial scenario model evaluates potential share price trajectories through Fiscal Year 2031 (5 years post-FY26 base). The model assumes a starting baseline share price of $15.12 and 41.33 million current diluted shares outstanding [cite: 9, 11, 19].
| Scenario | Year 5 Revenue Target (FY31) | Margin / Earnings Assumptions | Valuation Multiple Assumption | Current Share Price (USD) | Implied Future Share Price (USD) | 5-Year Total Return | Annualized Return (CAGR) | Subjective Probability |
|---|---|---|---|---|---|---|---|---|
| High Case | $550.0 Million [cite: 4] | 62.0% Gross Margin / 12.0% GAAP Net Margin ($66.0M Net Income) [cite: 2, 4, 6] | 3.5x Price/Sales (22.5x P/E) [cite: 1] | $15.12 [cite: 9, 11, 19] | $45.29 | +199.5% | +24.5% | 25% |
| Base Case | $460.0 Million [cite: 4] | 58.0% Gross Margin / 8.0% GAAP Net Margin ($36.8M Net Income) [cite: 2, 5, 6] | 2.0x Price/Sales (25.0x P/E) [cite: 1] | $15.12 [cite: 9, 11, 19] | $21.15 | +39.9% | +6.9% | 50% |
| Low Case | $362.0 Million [cite: 4] | 52.0% Gross Margin / 1.0% GAAP Net Margin ($3.62M Net Income) [cite: 2, 4, 6] | 1.0x Price/Sales (12.0x EV/EBITDA) [cite: 1, 9] | $15.12 [cite: 9, 11, 19] | $8.04 | -46.8% | -11.7% | 25% |
Calculating the probability-weighted fair value over the 5-year investment horizon:
$\text{Target Price} = (0.25 \times \$45.29) + (0.50 \times \$21.15) + (0.25 \times \$8.04)$
$\text{Target Price} = \$11.32 + \$10.58 + \$2.01 = \mathbf{\$23.91}$
The probability-weighted price target of $23.91 implies a 5-year total upside of 58.1% relative to the current share price of $15.12 [cite: 9, 11, 19].
ASYMMETRIC UPSIDE POTENTIAL
Blended Qualitative Score: 5.9 / 10
TRANSITION IN PROGRESS
AngioDynamics is executing a structural transition from a mature medical device supplier into a focused medical technology platform company [cite: 2, 3]. The operational thesis rests on three core catalysts:
The thesis is balanced by near-term operational risks, including executive transition execution, manufacturing transition handoffs, and working capital cash management [cite: 12, 16]. Overall, the company's valuation reflects an asymmetrical risk-reward profile as gross margin expansion and revenue mix shifts materialize [cite: 1, 4, 5].
PIVOT DRIVES VALUE
AngioDynamics common stock trades at $15.12, consolidating near its 50-day moving average of $15.18 and maintaining a position above its 200-day moving average of $12.40, which signals an underlying medium-term upward trend [cite: 9, 18, 19]. The 14-day Relative Strength Index (RSI) stands at 43.05, indicating neutral technical momentum [cite: 9]. Near-term price action points toward continued range-bound trading between $14.50 and $16.00 as the market monitors the CEO leadership handoff on November 2, 2026, and tracks cash flow stabilization in subsequent fiscal quarters [cite: 5, 12, 16].
BULLISH CONSOLIDATION PHASE
View AngioDynamics, Inc. (ANGO) stock page
Loading the interactive version of this report…